Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter
The ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/flutter (AF/AFL). ATHENA was the first trial to demonstrate a CV outcomes benefit, specifically reduced CV hospitalizations, with an antiarrhythmic drug. The objective of this study was to assess the impact of dronedarone treatment on healthcare resource utilization among real-world patients with AF/AFL in United States clinical practice.
This retrospective cohort study used claims data from the MarketScan® databases (Truven Health, Durham, NC, USA) to identify patients with ≥2 concurrent de novo pharmacy claims for dronedarone (≥180 days’ total supply) between June 2009 and March 2011, and with an AF/AFL diagnosis and no heart failure-related hospitalization during the 12 months preceding the initial (index) dronedarone claim. Annualized inpatient and outpatient resource utilization were compared between the pre-index (baseline) and post-index (follow-up) periods.
In total, 5,656 AF/AFL patients were prescribed dronedarone for ≥6 months and were followed for mean (standard deviation) 11.9 (4.7) months. Reductions in mean numbers of annualized all-cause, CV- and AF-related hospitalizations (~40–45%), and emergency department visits (~30–45%) were realized. These benefits were offset by increases in office visits (~10–30%) and AF-related prescription claims (74%) after dronedarone initiation. The sub-cohort of patients switching to dronedarone from Prior Rhythm-Control therapy (n = 2,080) showed similar reductions in hospital and emergency department events.
This study suggests that dronedarone use in real-world practice, as in the ATHENA trial, results in substantial reductions in hospital admissions, both in first-line and second-line antiarrhythmic treatment settings.
- Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534–9. CrossRef
- Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–84. CrossRef
- Estes NA 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, et al. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and the physician consortium for performance improvement (writing committee to develop clinical performance measures for atrial fibrillation) developed in collaboration with the Heart Rhythm Society. J Am Coll Cardiol. 2008;51:865–84. CrossRef
- Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52. CrossRef
- Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–64. CrossRef
- Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Seward JB, et al. Changing trends of hospital utilization in patients after their first episode of atrial fibrillation. Am J Cardiol. 2008;102:568–72. CrossRef
- Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–12. CrossRef
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. CrossRef
- Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78. CrossRef
- Freemantle N, Strack T. Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. J Clin Epidemiol. 2010;63:1053–8. CrossRef
- Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37. CrossRef
- Wieringa NF, de Graeff PA, van der Werf GT, Vos R. Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use. Eur J Clin Pharmacol. 1999;55:537–44. CrossRef
- Wieringa NF, Vos R, van der Werf GT, van der Veen WJ, de Graeff PA. Co-morbidity of ‘clinical trial’ versus ‘real-world’ patients using cardiovascular drugs. Pharmacoepidemiol Drug Saf. 2000;9:569–79. CrossRef
- Lakdawalla D, Turakhia MP, Jhaveri M, Mozaffari E, Davis P, Bradley L, et al. Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. J Comp Eff Res. 2013;2:301–12. CrossRef
- Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open. 2012;2(pii: e001768).
- Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol. 2010;33:270–9. CrossRef
- Hansen LG, Chang S. Health research data for the real world: the MarketScan databases. MarketScan White Paper 2012. http://www.truvenhealth.com/assets/2012_Truven_MarketScan_white_paper.pdf. Accessed 8 Jan 2014.
- International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 8 Jan 2014.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. CrossRef
- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70. CrossRef
- Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:223–42. CrossRef
- Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–76. CrossRef
- U.S. Food and Drug Administration. Multaq (dronedarone): Drug Safety Communication—Increased Risk of Death or Serious Cardiovascular Events. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264204.htm. Accessed Sept 24 2013.
- Heijman J, Heusch G, Dobrev D. Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights Cardiol. 2013;7:127–40.
- Naccarelli GV, Wolbrette DL, Levin V, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol. 2011;5:103–19. CrossRef
- Patel PD, Bhuriya R, Patel DD, Arora BL, Singh PP, Arora RR. Dronedarone for atrial fibrillation: a new therapeutic agent. Vasc Health Risk Manag. 2009;5:635–42. CrossRef
- Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS guideline recommendations: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1935–44. CrossRef
- Amin A, Jhaveri M, Lin J. Hospital readmissions in US atrial fibrillation patients: occurrence and costs. Am J Ther. 2013;20:143–50. CrossRef
- Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KS. Estimation of total incremental health care cost in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313–20. CrossRef
- American College of Cardiology, Institute for Healthcare Improvement. Hospital to Home, Reducing Readmissions, Improving Transitions (H2H National Quality Improvement Initiative). http://www.h2hquality.org. Accessed 24 Sept 2013.
- Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy. 2009;29:1417–26. CrossRef
- Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Advances in Therapy
Volume 31, Issue 3 , pp 318-332
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Atrial fibrillation
- Atrial flutter
- Cardiovascular hospitalizations
- Industry Sectors
- Author Affiliations
- 1. Warren Alpert Medical School of Brown University and Lifespan Cardiovascular Institute, 593 Eddy Street, APC 739, Providence, RI, USA
- 2. Novosys Health, Flemington, NJ, USA
- 3. Sanofi-aventis US, Bridgewater, NJ, USA